FDA approves Strensiq (asfotase alfa) to treat hypophosphatasia- Alexion
Alexion Pharmaceuticals has announced that the FDA has approved Strensiq (asfotase alfa) for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP). Asfotase alfa, an enzyme replacement therapy (ERT), is the first therapy approved in the US for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare metabolic disease in which patients experience on multiple systemic effects leading to debilitating or life-threatening complications.
Comment: Strensiq is approved in the EU, Japan and Canada.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins